Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorImam Abdulrahman Bin Faisal University

About this trial

Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC.

This multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles.

We hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients >18 years old with a confirmed diagnosis of SCD.

Presenting with a VOC.

NPRS >5

Willingness to participate and provide informed consent.

Disqualifiers

Patient requiring specialized IVF management as per the treating physician discretion.

Patients with congestive heart failure, and /or acute or chronic symptomatic systolic heart failure

Patients with ESRD on chronic dialysis

Patients with signs of shock (low SBP <100 or MAP < 65) and signs of hypo perfusion

Trial design

Design model

Parallel

Treatments tested in this trial

  • Sodium Chloride (NaCl) 0.9 %

    Drug

    Keep vein open rate

  • Sodium Chloride (NaCl) 0.9 %

    Drug

    IV bolus of 20 mL/kg of normal saline over 1 hour, followed by maintenance fluids at 1.5-2 ml/kg times the calculated daily maintenance requirements

Treatment groups

394 Participants
are divided into 2 treatment groups
Group A: Restricted approach groupExperimental treatment 1 intervention
Group B: Liberal Approach GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Pain intensity

Measured using the Numeric Pain Rating Scale (NPRS)

Time frame
Baseline (within 30 minutes post admission), 1 hour, then hourly until ED discharge or 24- 48- and 72-hours post-admission ( for admitted patients)

Secondary outcomes

1

Time to pain resolution

NPRS score of ≤5

Time frame
up to 4 hours
2

ED length of stay

time elapsed from ED admission to ED discharge or admit to the wards

Time frame
at least 4 hours
3

Hospital admission rate

Proportion of participants requiring inpatient admission

Time frame
within 24 hours of ED admission
4

Cumulative Opioid Dose

Total opioid consumption during acute VOC episode

Time frame
up to 4 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.